Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NF kappa B ligand. OPG has been shown to be an important inhibitor of osteoclast differentiation and activation in rodent models. Estrogen is known to suppress bone resorption, and the action of estrogen on bone may be mediated by OPG. The relationship between endogenous estrogen and circulating OPG levels and bone status in human populations is unclear. Thus, the aim of this study was to investigate the relationship between biochemical markers of bone turnover and bone density and circulating OPG and endogenous estradiol levels in a population-based cohort of postmenopausal women. Subjects were 180 women ages 55-91 yr (mean age, 67 yr). Serum estradiol was measured using an auto-analyzer. Serum concentrations of OPG were determined by ELISA. Markers of bone formation and resorption were measured by standard methods. Bone mineral density at total body, total hip, femoral neck, and lumbar spine was measured by dual energy x-ray absorptiometry. There was a significant inverse relationship between estradiol and all bone turnover markers (r-values from -0.46 to -0.23; P < 0.05). Serum estradiol was positively related to absolute bone density at all sites and to change in bone density at the hip and femoral neck by univariate analysis (r-values from 0.15-0.29; P < 0.05). We observed a weak inverse association between OPG and serum-based bone turnover markers (r-values -0.18 and -0.16; P < 0.05). There was a significant positive relationship between OPG and bone mineral density at total body, total hip, and femoral neck (r-values from 0.17-0.2; P < 0.05) by univariate analysis, which was lost after adjustment for age and body mass index. There was a significant weak positive relationship between circulating OPG and serum estradiol (r = 0.18; P < 0.02). We observed no significant relationships between OPG and bone turnover markers measured in urine. We conclude that the variation in circulating endogenous estradiol levels is an important factor contributing to levels of bone turnover and bone density at the menopause. Our observations also suggest that circulating levels of OPG may reflect OPG activity in bone and are related to circulating endogenous levels of estradiol. We have previously reported high levels of variability in urine markers of bone resorption, and we suggest that this could account for the absence of a significant association between these markers and circulating OPG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Age appears to be a major factor influencing OPG levels in nearly all studies (372-377).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 1×
“The mean age of this group at the 5-yr visit was 67 yr (8).”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 1×
“in transgenic mice designed to overexpress OPG, which develop osteopetrosis (8, 11).”
BackgroundIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · cited 1×
“The discovery of OPG in 1997 has enhanced our understanding of the way in which the processes of bone remodeling are regulated (8, 9 ). In vitro and animal studies have unambiguously revealed the role of OPG as a decoy receptor for receptor activator of NFB ligand (RANKL), neutralizing the effect of RANKL on the diffe…”
BackgroundSevere osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · cited 5×
“• Circulating Estradiol and OPG J Clin Endocrinol Metab, October 2002, 87(10):4470–4475 4471”
BackgroundInfluentialGarnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 2×
“osteoprotegerin (OPG) in human osteoblast-like cells (7).”
BackgroundRole of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 3×
“(18), there was no relationship between OPG and bone density.”
BackgroundThe effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · cited 1×
“OPG has also been administered as a therapeutic agent, resulting in a dramatic reduction in bone turnover state, but little is known of its long-term effect on bone density (15).”
BackgroundEpidemiology of Vertebral Fractures
Schousboe, J. T. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.004 · Cited by 451
Cited by
Items 101–200 of 202
Reyes‐García, R., Muñoz‐Torres, M., García, D. F., Mezquita‐Raya, P., Salcedo, J. A. G., & Luna, J. D. D. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181ac0cc1 · Cited by 17
Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?
Moreno, P. R., García, R. R., García‐Martin, A., Varsavsky, M., Garcia-Salcedo, J. A., & Muñoz‐Torres, M. (2013) · PubMed · doi:10.3275/8285 · Cited by 15
Chen, C., Huang, L., Chen, Y., Jin, J., Xu, Z., Liu, F., Li, K., & Sun, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-60514-8 · Cited by 14
“A cohort study found that serum levels of OPG were positively correlated with BMD 38 .”
InfluentialTodenhöfer, T., Hennenlotter, J., Schmiedel, B. J., Hohneder, A., Grimm, S., Kühs, U., Salih, H. R., Bühring, H., Fehm, T. N., Gakis, G., et al. (2012) · The Prostate · doi:10.1002/pros.22551 · Cited by 14
“BMD has been shown to signficantly correlate with OPG [21].”
ResultStarlinger, J., Kaiser, G., Thomas, A., & Sarahrudi, K. (2019) · Bone and Joint Research · doi:10.1302/2046-3758.87.bjr-2018-0116.r3 · Cited by 14
Regulatory Perspectives in Pharmacometric Models of Osteoporosis
Madrasi, K. J., Li, F., Kim, M., Samant, S., Voss, S. D., Kehoe, T. E., Bashaw, E. D., Ahn, H. Y., Wang, Y., Florian, J., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1071 · Cited by 14
RANKL elevation activates the NIK/NF-κB pathway, inducing obesity in ovariectomized mice
Mori, K., Mizokami, A., Sano, T., Mukai, S., Hiura, F., Ayukawa, Y., Koyano, K., Kanematsu, T., & Jimi, E. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0424 · Cited by 14
Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment
Josse, R. G. (2007) · Current Opinion in Oncology · doi:10.1097/01.cco.0000266465.24079.63 · Cited by 13
Serum osteoprotegerin levels are related to height loss: The Tromsø Study
Jørgensen, L., Hansen, J., Brox, J. H., Mathiesen, E. B., Vik, A., & Jacobsen, B. K. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9555-8 · Cited by 15
“Only few longitudinal studies are available, and whereas we found that high OPG levels were associated with bone loss in postmenopausal women not using HRT [16], two other (but much smaller) studies found no relationship [34, 41].”
BackgroundWu, X., Wu, X.-P., Luo, X., Xie, H., Zhang, H., Peng, Y., Yuan, L., Jiang, Y., & Liao, E.-Y. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.05.006 · Cited by 13
“In postmenopausal women, the circulating OPG level is a decisive factor affecting bone turnover, changes in bone mass, and the prevalence of vertebral fractures [23,24].”
BackgroundWu, X., Wu, X., Xie, H., Zhang, H., Luo, X., Liu, S., Peng, Y., Dai, R.-C., & Liao, E.-Y. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.11.024 · Cited by 13
Ricci, P., Tauchmanovà, L., Risitano, A. M., Carella, C., Mazziotti, G., Lombardi, G., Colao, A., Rotoli, B., & Selleri, C. (2006) · Transplantation · doi:10.1097/01.tp.0000244588.42519.72 · Cited by 14
“Paradoxically, serum OPG (sOPG) was found increased in postmenopausal osteoporosis and in several other conditions characterized by bone loss such as Paget disease, lytic bone metastases, or rheumatoid arthritis (14,15); this increase was interpreted as a compensatory mechanism consequent to bone demineralization.”
BackgroundResultUgay, L., Kochetkova, E., Афанасьевна, Н. В., & Maistrovskaia, Y. V. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.185857 · Cited by 16
“Indeed, while Rogers et al.[38] established a negative correlation between OPG and the bone formation markers, the data from Pobeha et al.[35] showed no relation between plasma OPG and RANKL levels and bone turnover markers in COPD.”
BackgroundMARKERS OF BONE METABOLISM IN EUGONADAL FEMALE PATIENTS WITH β-THALASSEMIA MAJOR
Angelopoulos, N., Goula, A., Katounda, E., Rombopoulos, G., Kaltzidou, V., Kaltsas, D., Konstandelou, E., & Tolis, G. (2007) · Pediatric Hematology and Oncology · doi:10.1080/08880010701533611 · Cited by 14
“[23] found a significant positive relationship between OPG and BMD of total body, total hip, and femoral neck, which was not statistically important after adjustment for age and BMI.”
BackgroundResultRzepka, R., Dołęgowska, B., Sałata, D., Rajewska, A., Budkowska, M., Domański, L., Kwiatkowski, S., Mikołajek-Bedner, W., & Torbè, A. (2015) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-015-0559-3 · Cited by 13
“Some proinflammatory cytokines can increase this process, while glucocorticosteroids, parathormone, and fibroblast growth factor decrease this process [18, 19].”
BackgroundChanges in forearm bone mass and bone size after menopause--a mean 24-year prospective study.
Svejme, O., Ahlborg, H. G., & Karlsson, M. K. (2012) · PubMed · Cited by 16
Karlsson, M. K., Ahlborg, H. G., Svejme, O., Nilsson, J., & Rosengren, B. E. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.01.006 · Cited by 12
“Estrogen suppresses bone resorption (20) and bone turnover (21) and inhibits bone widening (22e25), at least partly explaining why boys at puberty grow a wider skeleton than”
BackgroundPiatek, S., Adolf, D., Wex, T., Halangk, W., Klose, S., Westphal, S., Amthauer, H., & Winckler, S. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.01.005 · Cited by 13
Osteoprotegerin and C-telopeptide of type I collagen in Polish healthy children and adolescents.
Gajewska, J., Ambroszkiewicz, J., & Laskowska–Klita, T. (2006) · PubMed · Cited by 17
Tamaki, J., Iki, M., Morita, A., Ikeda, Y., Sato, Y., Kajita, E., Kagamimori, S., Kagawa, Y., & Yoneshima, H. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0965-3 · Cited by 12
“However, a number of studies did not find significant associations between OPG values and BMD [18, 19].”
BackgroundThe Impact of Sex Hormone Changes on Bone Mineral Deficit in Chronic Renal Failure
Doumouchtsis, K., Perrea, D. N., & Doumouchtsis, S. K. (2009) · Endocrine Research · doi:10.1080/07435800903127598 · Cited by 13
“Perturbations in OPG concentrations in sex hormone deficiency states may serve as a protective mechanism or a causative factor in conditions such as post-menopausal osteoporosis (34).”
BackgroundMenzel, J., di Giuseppe, R., Biemann, R., Aleksandrova, K., Kuxhaus, O., Wittenbecher, C., Fritsche, A., Schulze, M. B., Isermann, B., Boeing, H., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0544-3 · Cited by 12
“Nonetheless, experimental studies indicate an OPG-dependent bone remodeling mechanism, whereas human studies have provided controversial results regarding the relationship of OPG on bone remodeling marker and BMD [39–42].”
ResultAssociation of Endogenous Hormones and Bone Mineral Density in Postmenopausal Women
García-Alfaro, P., García, S., Rodríguez, I., Pascual, M. A., & Pérez-López, F. R. (2023) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_115_23 · Cited by 11
“The decline in estrogen levels in postmenopausal women was associated with low BMD [5,28] and increased risk of osteoporotic fractures.”
BackgroundOsteoprotegerin is associated with hip fracture incidence: the Tromso Study
Jørgensen, L., Hansen, J., Ahmed, L. A., Bjørnerem, Å., Emaus, N., Joakimsen, R. M., Mathiesen, E. B., Störmer, J., Vik, A., & Jacobsen, B. K. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys063 · Cited by 12
Effect of Nicotine on RANKL and OPG and Bone Mineral Density
Mızrak, S., Turan, V., İnan, S., Uysal, A., Yılmaz, C., & Ercan, G. (2014) · Journal of Investigative Surgery · doi:10.3109/08941939.2014.916369 · Cited by 11
“In some studies, no association was found between BMD and OPG [20, 21], whereas others demonstrated a significant inverse correlation between OPG and BMD, particularly in postmenopausal women without any hormone replacement therapy [22, 23].”
ResultThe effect of transvaginal estradiol on bone in aged women: A randomised controlled trial
Salminen, H., Sääf, M., Johansson, S., Ringertz, H. G., & Strender, L. (2007) · Maturitas · doi:10.1016/j.maturitas.2007.03.005 · Cited by 11
Measurement of Biochemical Markers of Bone Formation
Naylor, K. E., & Eastell, R. (2006) · Elsevier eBooks · doi:10.1016/b978-012088562-6/50033-9 · Cited by 12
Self-citationBalsa, J. A., Lafuente, C., Gómez‐Martín, J. M., Galindo, J., Peromingo, R., García‐Moreno, F., Velasco, G. R., Martínez-Botas, J., Gómez‐Coronado, D., Escobar-Morreale, H. F., et al. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0712-0 · Cited by 11
“This is in conceptual agreement with other studies that have demonstrated an association of the OPG/RANKL system with several bone markers [22, 24, 25].”
ResultRelationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women
Xie, G., Lei, D.-D., He, H., Gong, J., Chen, C., Chen, P., Zhang, H., Luo, X., Liao, E.-Y., & Wu, X. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.04.019 · Cited by 12
Zhang, N., Wu, X., Wu, X., Fu, X., Du, X.-Y., Xie, H., Peng, Y., Luo, X., & Liao, E.-Y. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.01.021 · Cited by 10
Osteoporosis: Pathogenesis, New Therapies and Surgical Implications
Labovitz, J. M., & Revill, K. P. (2007) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2006.12.002 · Cited by 9
Giusti, M., Cecoli, F., Fazzuoli, L., Franchis, V. D., Ceresola, E., Ferone, D., Mussap, M., & Minuto, F. M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.01.004 · Cited by 9
“Serum OPG is correlated with BMD in postmenopausal women [50] but not in men [49].”
BackgroundLedoux, C., Boaretti, D., Sachan, A., Müller, R., & Collins, C. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901720 · Cited by 9
“…et al., 1984) pM 11.1 – 122.7 (Mödder et al., 2011); 27.5 (Dick et al., 2005); 27.9 (Devine et al., 2004); 38.9 (García-Martín et al., 2011); 61.0 (Rogers et al., 2002); 90 – 120 (Slemenda et al., 1987); 151.4 (Wu et al., 2010); (156.5 OP 172.1 non − OP ) (Jabbar et al., 2011) C sclerostin pg/ml…”
InfluentialVertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females
Li, X., Zuo, X., Li, L., Xu, R., Wang, Y., Chang, S., Wang, Y., Luo, P. F., & Li, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1442046 · Cited by 8
Zakaria, Z., Hamid, W. Z. W. A., & Mohamed, M. (2021) · Sains Malaysiana · doi:10.17576/jsm-2021-5007-12 · Cited by 8
“It is well known that oestrogen deficiency is the main contributory factor to postmenopausal osteoporosis (Rogers et al. 2002).”
Norian, J. M., Zeitlian, G., Adel, G., Freeman, R. G., Santoro, N. F., & Pal, L. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.11.089 · Cited by 8
Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M. (2003) · Bone · doi:10.1016/j.bone.2003.08.001 · Cited by 7
“05) in a cohort of 180 women ages 55–91 [24].”
Vethencourt, A., Trinidad, E. M., Dorca, E., Petit, A., Soler-Monsó, M. T., Ciscar, M., Barranco, A., Pérez-Chacón, G., Jimenez, M., Rodríguez, M., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-01996-w · Cited by 7
“The complexity of interpreting biomarker dynamics is underscored by factors such as bone mineral density, body mass index, and cardiovascular disease, which were not collected at enrollment [51, 52].”
Challenges in Clinical Patient Management
Aapro, M. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.501648 · Cited by 7
A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease
Dugard, M.-N., Sharp, C. A., Evans, S. F., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. E. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.01.020 · Cited by 8
Association of osteoprotegerin and rankl levels with insulin resistance in pubertal obese children
Yeşilkaya, E., Bıdecı, A., Camurdan, O. M., Boyraz, M., Vurucu, S., & Cınaz, P. (2009) · Open Medicine · doi:10.2478/s11536-009-0065-y · Cited by 6
“Review of the literature suggests a correlation between OPG and BMD, particularly in chronic disorders [10,11,17,22].”
BackgroundInfluentialRole of interleukin-6 on RANKL-RANK/osteoprotegerin system in hypothyroid ovariectomized mice.
Myśliwiec, J., Zbucki, R. L., Nikołajuk, A., Myśliwiec, P., Taranta, A., Kamiński, K. A., Bondyra, Z., Dadan, J., Górska, M., & Winnicka, M. M. (2011) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0064-5 · Cited by 6
Chen, C., Liang, M.-K., Zhang, H., Peng, Y., Wu, X., Wu, X., & Liao, E.-Y. (2013) · Endocrine Research · doi:10.3109/07435800.2013.840654 · Cited by 6
“ing OPG level is a decisive factor affecting bone turnover, changes in bone mass and the prevalence of vertebral fractures (6,7).”
BackgroundIncidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
Lee, H. W., Kwon, S., Moon, Y. R., Ahn, H., Lee, J., & Ahn, S. H. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16982 · Cited by 5
“Menopause-related bone loss, resulting from estrogen deficiency, leads to an increase in bone resorption as compared with formation [22].”
Park, S. S., Uzelac, A., & Kotsopoulos, J. (2022) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-022-00223-3 · Cited by 6
“Other studies also found mixed, and often weak, associations with OPG levels in healthy women with circulating endogenous sex hormones, such as estradiol, menopause, and HRT use [40, 72, 78, 79].”
ResultWhen Lowest Dose for Shortest Amount of Time Does Not Apply
Faubion, S. S., Files, J. A., & Rocca, W. A. (2016) · Journal of Women s Health · doi:10.1089/jwh.2016.5781 · Cited by 5
Roelfsema, F., Yang, R. J., Bowers, C. Y., & Veldhuis, J. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02639 · Cited by 5
Menopausia: nuevas evidencias, nuevos enigmas
Malacara, J. M. (2003) · Revista de enfermedades infecciosas en pediatría · Cited by 7
Hamed, E. A., Mohamed, N., El‐Metwally, T. H., & Kamal, M. M. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181d419d6 · Cited by 6
Negi, D., Bharti, M., Thakur, Y., & Singh, Y. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124529 · Cited by 4
Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy.
Styczyńska, H., Lis, K., Sobańska, I., Pater, A., Pollak, J., & Mańkowska‐Cyl, A. (2009) · PubMed Central · Cited by 6
Serum estradiol levels and bone mineral density in postmenopausal women
Mawi, M. (2010) · Universa Medicina · doi:10.18051/univmed.2010.v29.90-95 · Cited by 4
“a positive association was found between estradiol and bone density at all body sites examined.(21) In another study, it was found that increased age was associated with decreased estradiol and BMD, because reduced serum estradiol concentrations increased bone turnover, which is a risk factor for fractures.”
BackgroundOsteoprotegerin: a valid new marker of bone turnover in post-menopausal osteoporosis?
Ulivieri, F. M., Piodi, L. P., Marchelli, D., Corradini, C., Verdoia, C., & Gherardi, P. G. (2005) · Journal of Orthopaedics and Traumatology · doi:10.1007/s10195-005-0087-4 · Cited by 4
Los estrógenos y el hueso: revisión de la evidencia
Calderón, A. M. (2005) · Progresos de Obstetricia y Ginecología · doi:10.1016/s0304-5013(05)72361-x · Cited by 9
Laboratory Assessment of Postmenopausal Osteoporosis
Garnero, P., & Delmas, P. D. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0388 · Cited by 4
Biochemical markers in bone disease
Naylor, K. E., & Eastell, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00200-x · Cited by 4
Self-citationEndocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Does Anastrozole Affect Bone Resorption Similarly in Early and Late Postmenopausal Women?
Powell, D., Cochrane, R., & Davie, M. W. J. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9452-2 · Cited by 3
“The reduction of estradiol levels following menopause is held to be responsible for the decline in bone mineral density (BMD) and for an increase in bone-resorption markers and fracture risk [6–9].”
BackgroundWu, X., Peng, Y., Zhang, H., Xie, H., Sheng, Z., Luo, X., Dai, R.-C., Zhou, H., Wu, X.-P., & Liao, E.-Y. (2013) · International Journal of Endocrinology · doi:10.1155/2013/727164 · Cited by 3
“In postmenopausal women, the circulating OPG level affects bone turnover, changes in bone mass, and the prevalence of vertebral fractures [6, 7].”
BackgroundMammographic arterial calcifications: Cardiovascular risk factors, pregnancy and lactation
van der Schouw, Y. T., Beijerinck, D., Mali, M. A., & van der Graaf, Y. (2006) · Cited by 3
Beyond Estrogen Deficiency: The Independent Role of FSH in Site-Specific Bone Loss in Midlife Women
Stieben, L. A. R., Brun, L. R., Pustilnik, E., Doddi, P. N., Pellizzón, N. A., Acosta, J., & Brance, M. L. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01450-1 · Cited by 2
Chen, C., Liu, Y., Lin, S.-C., Wang, C., Shen, W., Cho, D., Lee, T.-Y., Juan, C., Juan, C.-E., Cheng, K.-Y., et al. (2022) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-022-00746-z · Cited by 2
“Our results can be explained by the mixed effects of estrogen deficiency related bone resorption acceleration and the aging related bone formation deceleration [24, 25].”
BackgroundOsteoprotegerin: A neutralizing receptor, protector of bones and a potential antiresorptive agent
Andjelkovic, Z., Katić, V., Mihajlović, D., Zivkovic, V. D., Petrović, A., & Lalošević, D. (2005) · Medicinski pregled · doi:10.2298/mpns0508362a · Cited by 2
Novel inflammatory markers of labor following premature preterm rupture of membranes
Rzepka, R., Dołęgowska, B., Marczuk, N., Kwiatkowski, S., Rajewska, A., Nurek, K., & Torbè, A. (2019) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog4607.2019 · Cited by 2
Ovariectomized rat model and shape variation in the bony labyrinth
Ward, D. L., Schroeder, L., Tinius, A., Niccoli, S., Voth, R., Lees, S. J., Silcox, M. T., Viola, B., & Sanzo, P. (2022) · The Anatomical Record · doi:10.1002/ar.24878 · Cited by 2
“A connection between oral contraceptive use, hormone replacement therapy, and multiple pregnancies with otosclerosis, hearing changes, and other vestibular disorders is known (Guimaraes et al., 2006; Horner, 2009; Mitre et al., 2006; Ryback, 1995).”
BackgroundPreventive effect of Total ethanolic extract of Butea monosperma on bone loss in osteopenic rats
Khanka, S., Lakra, A., Gupta, R., Sharma, K., Maurya, R., Chattopadhyay, N., & Singh, D. R. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i7.5887 · Cited by 2
Die Rolle von RANK-Ligand und Osteoprotegerin bei Osteoporose
Hofbauer, L. C. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 4
Huang, L., Chen, L., Wu, P., & Hsu, P.-H. (2026) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2026.101723 · Cited by 1
Fisiología del hueso y marcadores bioquímicos del recambio óseo
Canelas, A. C., Cenarruzabeitia, N. V., & Corrales, E. P. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-503-5.00002-2 · Cited by 2
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
Canney, P. A. (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s11835 · Cited by 1
Bone Mineral Density And Endogen Sex Steroid Hormone Association in Postmenopausal Healthy Women
Safarova, A., Pala, H. G., Doğan, E., & Gezer, N. S. (2011) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.5505/tjod.2011.84755 · Cited by 1
“In menopause period, follicle development and cyclic estrogen secreting stops with the decrease of ovarian follicles responding to gonadotropins(1,2).”
BackgroundOh, K. W., Yun, E. J., Rhee, E., Lee, W., Baek, K. H., Kang, M. I., Park, C., Ihm, S. H., Choi, M. G., Yoo, H. J., et al. (2005) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2005.20.3.204 · Cited by 2
Rusda, M. (2017) · Public Health International Conference (PHICo) · doi:10.2991/phico-16.2017.4 · Cited by 1
“1%) who have osteoporosis, seen from the fourth characteristic of this subject, entirely included in the category of obese and with higher estradiol levels, these results prove the relationship of body mass index on bone density [13], [14].”
BackgroundLiu, J., Zhao, H., Ning, G., Zhao, Y., Chen, Y., Zh, L., Sun, L., Xu, Y., & Chen, J. L. (2005) · Cited by 1
Cauley, J. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-25976-5_5 · Cited by 2
Raisz, L. G. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-740-6_3 · Cited by 1
Risk factors for bone fragility and fracture in postmenopausal women
Svejme, O. (2013) · Lund University Publications (Lund University) · Cited by 2
Eviö, S. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 1
Doolittle, M. L. (2020) · UR Research (University of Rochester) · Cited by 1
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21 · Cited by 1
Breast Arterial Calcifications and Heart Disease Risk in women
Maas, A. H. E. M. (2006) · Utrecht University Repository (Utrecht University)
Estudio del metabolismo mineral óseo en el cáncer de próstata avanzado
Flores, S. Q. (2011) · Institutional Repository of the University of Granada (University of Granada)
Ashley, D. T. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University)
Dettmer, B. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1528
García, D. F. (2011) · Institutional Repository of the University of Granada (University of Granada) · Cited by 1
Mardock, M. A. (2003) · VTechWorks (Virginia Tech)
IMPLICATIONS OF OSTEOPROTEGERIN IN POSTMENOPAUSAL OSTEOPOROSIS
Cretu, A., Grigorie, D., Neacşu, E., & Chiovschi, S. I. (2003)
Cauley, J. A. (2009) · Springer eBooks · doi:10.1007/978-1-84628-697-1_4
Morningstar, M. W., Strauchman, M. N., & Fleischmann, G. (2016) · Open Journal of Internal Medicine · doi:10.4236/ojim.2016.61002
“[6], 180 women aging 55 91 were evaluated for bone markers and estrogen levels.”
BackgroundEffect of Adjuvant (Hormonal) Therapy on Bone Mineral Density in Caucasian Women with Breast Cancer
Khachidze, N., Giorgadze, E., Tsagareli, M., Dolidze, N., & Sulikashvvili, T. (2017) · European Scientific Journal ESJ · doi:10.19044/esj.2017.v13n18p1
Sanders, L. J., & Frykberg, R. G. (2008) · Elsevier eBooks · doi:10.1016/b978-84-8086-367-4.50012-6
Factores asociados a dolores musculares y articulares en mujeres afrodescendientes climatéricas
de la Mujer, G. D. I. S., Monterrosa-Castro, Á. D. J., Romero-Martínez, G., & Monterrosa‐Blanco, A. (2022) · Revista de Obstetricia y Ginecología de Venezuela · doi:10.51288/00820107 · Cited by 1
Anti-Aging Medicine LiteratureWatch
(2003) · Rejuvenation Research · doi:10.1089/109454503765361588
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt027
Park, S. S., Zaman, T., Kim, S. J., Brooks, J. D., Wong, A. K. O., Lubiński, J., Narod, S. A., Salmena, L., & Kotsopoulos, J. (2023) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-0577
Martínez, Y. S., Arriaga, R. E. V., López, S. G., & Molina‐Frechero, N. (2024) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v65i4.30321
Pharmacotherapy Options in Cancer Treatment-induced Bone Loss: Focus on Bisphosphonates
Ito, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2064
Ng, P. K. L., & Clark, P. F. (2008) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.184462
周, 歆. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161311
Metadata
- Authors
- Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R.
- Affiliations
- University of Sheffield (GB)
- Sheffield Hallam University (GB)
- Corresponding author
- Rogers, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4470-4475
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1972546618
- Cited by
- 200
- References
- 20
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 3 · 2013: 7 · 2012: 7
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- estradiol, osteoprotegerin, bone turnover markers, bone mineral density, postmenopausal women, estrogen, bone resorption, bone formation, RANKL, osteoclasts, menopause, hip bone density, femoral neck, lumbar spine, body mass index, age, bone loss prevention, osteoporosis
- MeSH terms
- Aged, Aged, 80 and over, Analysis of Variance, Estradiol, Female, Femur, Glycoproteins, Humans, Lumbar Vertebrae, Middle Aged, Regression Analysis, Biomarkers, Bone Density, Body Mass Index, Bone Remodeling, Postmenopause, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.